ArticleScientific reports2025
Metformin alleviates inflammatory response and severity rate of COVID-19 infection in elderly individuals.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The length of hospital stay in COVID-19 patients using pre-hospital metformin at a Saudi tertiary hospital: a retrospective cohort study.BMC infectious diseases · 2026Article
- Biguanides are associated with decreased early mortality and risk of acute kidney injury in hospitalised patients with COVID-19: a nationwide retrospective cohort study in Japan.Clinical and experimental nephrology · 2026Article
- A machine learning model exploring the relationship between chronic medication and COVID-19 clinical outcomes.International journal of clinical pharmacy · 2025Article
- Metabolic Reprogramming in Respiratory Viral Infections: A Focus on SARS-CoV-2, Influenza, and Respiratory Syncytial Virus.Biomolecules · 2025Review
- Post-COVID Metabolic Fallout: A Growing Threat of New-Onset and Exacerbated Diabetes.Biomedicines · 2025Review
- Control of type 2 diabetes in patients with cancer and chronic pro-inflammatory cytokines during the COVID-19 pandemic.Journal of medicine and life · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
To evaluate the relationship between metformin and the outcome of coronavirus disease 2019 (COVID-19) infection. The study included 413 patients with type 2 diabetes among the 5217 patients enrolled in a COVID-19 study, and analyzed whether receiving metformin therapy prior to infection was associated with risk of ICU admission, development of pneumonia and length of hospital stay. The study also examined the correlation between metformin treatment and levels of IL-6, CRP, serum ferritin (SF), lymphocyte, CD4 at admission, as well as the increase in open reading frame 1ab gene cycle threshold (ORF1abCT) after one week of hospitalization. There were no differences in age, sex, BMI, comorbidities, number of vaccine doses or eGFR between patients receiving and not receiving metformin therapy. In the ICU group, the proportion of patients not receiving metformin was 92.5%, significantly higher than the 69.2% of patients not admitted to ICU (p = 0.010). In the pneumonia group, the proportion of patients not receiving metformin was 78.6%, significantly higher than the 67.2% in the non-pneumonia group (p = 0.020). Compared with patients receiving no treatment, those receiving metformin had a shorter hospital stay (12.1 ± 5.9 days vs. 14.5 ± 8.2 days, p = 0.001). In the patients ≥ 60 years old, those receiving treatment had significantly lower levels of IL-6 (median, 12.3 pg/ml vs. 4.0 pg/ml, p = 0.026) and significantly higher levels of Lymphocyte (median, 1.2 × 10
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.